Research

1. Implementation and feasibility testing of the new Australian Scleroderma Interest Group algorithm for pulmonary arterial hypertension screening. ASIG has published a new screening algorithm for PAH screening in scleroderma to allow early detection of this serious complication and initiation of life-saving therapy. This new algorithm...

1. Prospective validation of the ASIG PAH screening algorithm One of ASIG’s key activities is the Australian Scleroderma Screening Program for early identification of heart and lung complications, such as pulmonary arterial hypertension (PAH). We have developed and validated a novel, cost-effective screening algorithm for PAH, using...

Assoc. Prof  Peter Yousef  - Department of Rheumatology, Royal Prince Alfred Hospital Subject: The utility of biomarkers of interstitial lung disease in systemic sclerosisContinuation of ASIG database extrapolation -  Over 1700 patients have contributed their data and biosamples annually to the ASIG database, many for several years. The...